CAS No.
[2628280-40-8 (Unlabeled)]
Storage Condition
Store at refrigerator (2-8°C) for long term storage
Application Notes
Useful research chemical for a range of applications
Hazard Compound
No -Refer MSDS for accurate information
Nirmatrelvir-d9 is a drug product that is used as an analytical standard for HPLC, as well as in research and development of drugs.
Refund Policy
We are committed to offering products of the highest quality in order to meet the needs of our customers, and have elaborate systems in
place to ensure that material specifications, their certification and all handling and storage conditions are communicated at the time of
material handover.
We have invested in the highest quality packaging materials and use international logistics partners to service our customers. While all
possible precautions have been taken to deliver the required product(s), there may be some rare situations when our product does not
meet your requirements. Should that arise, please contact us with your concerns and we will endeavour to address them on a priority
basis. If there is no other option, we will either replace your product(s) or issue a refund or account credit, whichever you prefer.
If there is an issue with one or more of our products, our policy is that it must be reported to us within 45 days of your receiving shipment.
While we will always address product issues after the 45 day return window has passed, we cannot issue a refund or account credit. As
always, we appreciate your support.
Nirmatrelvir-d9 usage and description
Nirmatrelvir-D9 is a deuterated form of the antiviral drug Nirmatrelvir, which is used in combination with other drugs to treat patients with COVID-19. This medication is classified as a protease inhibitor, which means it works by blocking the action of a specific enzyme that is needed by the virus to replicate and spread. By inhibiting this enzyme, Nirmatrelvir-D9 can help to reduce the severity of symptoms and shorten the duration of illness.
Chemically, Nirmatrelvir-D9 is a derivative of the original drug Nirmatrelvir, which contains hydrogen atoms in place of deuterium atoms. Deuterium is a stable isotope of hydrogen that is twice as heavy, making Nirmatrelvir-D9 a labeled compound that can be easily tracked and measured through scientific studies.
In clinical trials, Nirmatrelvir-D9 has shown promising results in reducing viral load and improving clinical outcomes in COVID-19 patients. This medication is typically administered orally and is generally well-tolerated, although some patients may experience side effects such as nausea, diarrhea, and headache.
Overall, Nirmatrelvir-D9 represents a promising new treatment option for patients with COVID-19 and may play an important role in helping to control the spread of the virus. Ongoing research is needed to fully understand the safety and effectiveness of this medication, but early results are encouraging and suggest that it may be a valuable tool in the fight against COVID-19.
